scholarly journals A novel culture method that sustains ERα signaling in human breast cancer tissue microstructures

2020 ◽  
Author(s):  
Ana Luísa Cartaxo ◽  
Marta F Estrada ◽  
Giacomo Domenici ◽  
Ruben Roque ◽  
Fernanda Silva ◽  
...  

Abstract Background Estrogen receptor α (ERα) signaling is a defining and driving event in most breast cancers; ERα is detected in malignant epithelial cells of 75% of all breast cancers (classified as ER-positive breast cancer) and, in these cases, ERα targeting is the main therapeutic strategy. However, the biological determinants of ERα heterogeneity and the mechanisms underlying therapeutic resistance are still elusive, hampered by the challenges in developing experimental models recapitulative of intra-tumoral heterogeneity and in which ERα signaling is sustained. Ex vivo cultures of human breast cancer tissue have been proposed to retain the original tissue architecture, epithelial and stromal cell components and ERα. However, loss of cellularity, viability and ERα expression are well-known culture-related phenomena. Methods BC samples were collected and brought to the laboratory. Then they were minced, enzymatically digested, entrapped in alginate and cultured for one month. The histological architecture, cellular composition and cell proliferation of tissue microstructures were assessed by immunohistochemistry. Cell viability was assessed by measurement of cell metabolic activity. The presence of ERα was accessed by immunohistochemistry and RT-qPCR and its functionality evaluated by challenge with 17−β−estradiol and fulvestrant, respectively. Results We describe a strategy based on entrapment of breast cancer tissue microstructures in alginate capsules and their long-term culture under agitation, successfully applied to tissue obtained from 63 breast cancer patients. After one month in culture, the architectural features of the encapsulated tissue microstructures were similar to the original patient tumors: epithelial, stromal and endothelial compartments were maintained with an average of 97 of cell viability compared to day 0. In ERα-positive cases, fibers of collagen, the main extracellular matrix component in vivo , were preserved. ERα expression was retained at gene and protein levels and response to ERα stimulation and inhibition was observed at the level of downstream targets, demonstrating active ER signaling. Conclusions The proposed model system is a new methodology to study ex vivo breast cancer biology, in particular ERα signaling. It is suitable for interrogating the long-term effects of anti-endocrine drugs in a set-up that closely resembles the original tumor microenvironment, with potential application in pre- and co-clinical assays of ERα-positive breast cancer.

Breast Cancer ◽  
1998 ◽  
Vol 5 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Shunzo Kobayashi ◽  
Hirotaka Iwase ◽  
Yoshihiko Kawarada ◽  
Naoyuki Miura ◽  
Toshihiro Sugiyama ◽  
...  

2004 ◽  
Vol 50 (8) ◽  
pp. 1356-1363 ◽  
Author(s):  
Nicolai Grebenchtchikov ◽  
Arend Brinkman ◽  
Simone P J van Broekhoven ◽  
Danielle de Jong ◽  
Anneke Geurts-Moespot ◽  
...  

Abstract Background: High concentrations of breast cancer anti-estrogen resistance 1 (BCAR1) protein measured by Western blotting in primary breast tumor cytosols are associated with early disease progression and failure of tamoxifen therapy. The aim of the present study was to develop an ELISA to measure BCAR1 quantitatively in extracts of human breast cancer tissue. Methods: A recombinant fragment of BCAR1 (the human homolog of murine p130Cas) was produced in bacterial M15 cells, purified, and injected into chickens and rabbits. The generated antibodies were affinity-purified and used for the construction of an ELISA. After validation, the results obtained with the ELISA were compared with Western blot findings on primary breast tumors. Results: The detection limit the BCAR1 ELISA was 0.0031 μg/L, and the within-run imprecision (CV) was <20% at concentrations down to 0.004 μg/L. The within-run imprecision (CV) was 1.0–7.2%, and the between-run CV was 3.6–5.4%. There was no cross-reactivity with family member HEF1. The assay exhibited parallelism of results between serial dilutions and a mean recovery (range) of 96 (79–118)%. Conclusions: The ELISA measures BCAR1 in human breast cancer cytosols with high sensitivity and specificity. The assay can be used to confirm and to quantitatively extend previous semiquantitative Western blot data on the prognostic and predictive value of BCAR1 in human breast cancer; it can also be applied for other diseases.


Cancer ◽  
1984 ◽  
Vol 53 (2) ◽  
pp. 301-305 ◽  
Author(s):  
Jorge E. Filmus ◽  
Osvaldo L. Podhajcer ◽  
Eduardo Mareso ◽  
Natalio Guman ◽  
José Mordoh

2011 ◽  
Vol 93 (5) ◽  
pp. 681-683 ◽  
Author(s):  
Ewa Sierko ◽  
Marek Z. Wojtukiewicz ◽  
Lech Zimnoch ◽  
Piotr Tokajuk ◽  
Walter Kisiel

Sign in / Sign up

Export Citation Format

Share Document